Batavia At LBSP ATMP TechTalks
Eize De Boer showed us what it takes to realize a new facility for Batavia Biosciences designed for viral vector manufacturing to support developers on a global scale.
The multi-product facility is designed to support the late-stage clinical manufacturing and commercial manufacturing of vaccines and viral vector-based gene therapy and immune-oncology products. Batavia’s highly intensified manufacturing technology, HIP-Vax®, which utilizes fixed-bed bioreactors, will be the main platform, but also products manufactured using traditional mammalian cell suspension technologies up to 1000L scale can readily be delivered.
The facility is based on a modular design, with 6 production suites. On-site, state-of-the-art fill / finish capabilities ensure on-time delivery of drug product. Depending on virus / vector type the facility is expected to provide for several hundred million doses annually.
Related
Adenovirus vectors: cutting edge delivery vehicles for gene therapy and vaccine development
Adenovirus vectors are vital to gene therapy, vaccine development, and cancer virotherapies. Learn more about these important delivery tools.
Taking your adenoviral vector product from R&D to the clinic
The road from R&D to final production of an adenoviral vector product is well trodden. Here is information to help you on your journey.
Driving down COGs of viral vector-based biopharmaceuticals
How do you keep cost of goods (COGs) for viral vector-based medicines within reason to develop a product that is both affordable and financially viable?
